switching from tirzepatide to semaglutide for maintenance Tirzepatide: Is It a Good Idea? Switching between weight-loss medications -

B.TvrdeicA.et al (2020b)

In spite of all available therapeutic tools, however, successful weight loss and maintenance are hardly accomplished

Clinical studies have demonstrated that tirzepatide can lead to significant improvements in blood sugar control by increasing insulin secretion in response to food and reducing glucose release from the liver

Across a number of threads with titles such as Did scientists accidentally invent an anti-addiction drug? and I don't know if this is a side effect but

This broader endocrine interaction reflects its ghrelin-mimetic nature

Major cardiovascular outcome trials include: LEADER trial (liraglutide): Demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk SUSTAIN-6 (semaglutide): Showed reduced cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke REWIND (dulaglutide): Confirmed cardiovascular benefits across a broad patient population SELECT trial (semaglutide): Showed reduced MACE in people with obesity without diabetes, though this evidence is not yet fully incorporated into UK labelling [17] These trials consistently found that the modest heart rate increases observed did not translate into adverse cardiovascular outcomes